Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Onyx Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00150462
First received: September 6, 2005
Last updated: January 3, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2010
  Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)